Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Key Terms
non-gaap gross margin financial
liquid biopsy medical
companion diagnostic regulatory
free cash flow financial
Second quarter 2026 revenue growth of
Raises 2026 revenue guidance to
Second Quarter 2026 Financial Highlights
For the three-month period ended June 30, 2026, as compared to the same period of 2025:
-
Reported total revenue of
$335.0 million 44% , driven by:-
Oncology revenue of
$219.1 million 38% , and approximately 104,000 oncology tests, an increase of63% -
Biopharma & Data revenue of
$60.9 million 9% -
Screening revenue of
$52.9 million $14.8 million
-
Oncology revenue of
-
Generated non-GAAP gross margin of
67% , compared to66% for the second quarter of 2025
Recent Operating Highlights
-
Received
U.S . Food and Drug Administration (FDA) approval for Guardant360® Liquid CDx, the most advanced FDA-approved liquid biopsy panel - Presented 38 abstracts at the 2026 American Society of Clinical Oncology Annual Meeting, highlighting the expanding clinical utility of Guardant’s portfolio
- Received FDA approval for Guardant360® CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS for HER2 (ERBB2)-mutant advanced non-small cell lung cancer
- Achieved inclusion of Shield in the American Cancer Society’s updated colorectal cancer screening guidelines
- Obtained Shield coverage from UnitedHealth Group, the first major commercial insurer to provide coverage
- Received FDA approval for higher-throughput, lower-COGS Shield workflow
“Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing
“Our team delivered another quarter of exceptional growth for Shield, and we are excited about several important milestones that reinforce its expanding role in colorectal cancer screening,” said AmirAli Talasaz, co-founder and co-CEO. “The inclusion of the Shield blood test in the American Cancer Society’s screening guidelines, together with UnitedHealth Group’s broad coverage decision, represents powerful validation of Shield’s clinical utility and its potential to improve access to screening.”
Second Quarter 2026 Financial Results
Revenue was
Gross profit, or total revenue less cost of revenue, was
Non-GAAP gross profit was
Operating expenses were
Net loss was
Non-GAAP net loss was
Adjusted EBITDA loss was
Free cash flow for the second quarter of 2026 was
Cash, cash equivalents, and restricted cash were
2026 Guidance
Guardant Health now expects full year 2026 revenue to be in the range of
Within this revenue range:
-
Oncology revenue is now expected to grow approximately
30% in 2026, compared to prior guidance of28% to29% . Oncology volume is now expected to grow to approximately50% in 2026, compared to prior guidance of approximately35% . - Biopharma & Data revenue growth is expected to be in the low double-digit range.
-
Screening revenue is now expected to be in the range of
$218 $230 million $186 $198 million
Guardant Health continues to expect full year 2026 non-GAAP gross margin to be in the range of
Webcast Information
Guardant Health will host a conference call to discuss the second quarter 2026 financial results after market close on Thursday, July 30, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.
Non-GAAP Measures
Guardant Health has presented in this release certain financial information in accordance with
We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other non-recurring items.
Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; contingent consideration; and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.
We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.
These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Guardant Health, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except per share data) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
|
|
|
|
|
|
|
|
||||||||
Revenue |
$ |
334,978 |
|
|
$ |
232,088 |
|
|
$ |
636,643 |
|
|
$ |
435,559 |
|
Costs and operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of revenue |
|
115,949 |
|
|
|
81,205 |
|
|
|
220,868 |
|
|
|
155,928 |
|
Research and development expense |
|
96,533 |
|
|
|
87,449 |
|
|
|
187,571 |
|
|
|
175,970 |
|
Sales and marketing expense |
|
189,954 |
|
|
|
119,588 |
|
|
|
359,086 |
|
|
|
223,904 |
|
General and administrative expense |
|
61,660 |
|
|
|
50,259 |
|
|
|
119,586 |
|
|
|
97,211 |
|
Total costs and operating expenses |
|
464,096 |
|
|
|
338,501 |
|
|
|
887,111 |
|
|
|
653,013 |
|
Loss from operations |
|
(129,118 |
) |
|
|
(106,413 |
) |
|
|
(250,468 |
) |
|
|
(217,454 |
) |
Interest income |
|
10,199 |
|
|
|
7,560 |
|
|
|
21,350 |
|
|
|
16,672 |
|
Interest expense |
|
(1,346 |
) |
|
|
(983 |
) |
|
|
(2,693 |
) |
|
|
(1,774 |
) |
Other income (expense), net |
|
308 |
|
|
|
(25 |
) |
|
|
151 |
|
|
|
7,826 |
|
Loss before provision for income taxes |
|
(119,957 |
) |
|
|
(99,861 |
) |
|
|
(231,660 |
) |
|
|
(194,730 |
) |
Provision for income taxes |
|
185 |
|
|
|
38 |
|
|
|
557 |
|
|
|
328 |
|
Net loss |
$ |
(120,142 |
) |
|
$ |
(99,899 |
) |
|
$ |
(232,217 |
) |
|
$ |
(195,058 |
) |
Net loss per share, basic and diluted |
$ |
(0.90 |
) |
|
$ |
(0.80 |
) |
|
$ |
(1.76 |
) |
|
$ |
(1.57 |
) |
Weighted-average shares used in computing net loss per share, basic and diluted |
|
132,867 |
|
|
|
124,114 |
|
|
|
132,074 |
|
|
|
123,993 |
|
Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) |
|||||||
|
June 30, 2026 |
|
December 31, 2025 |
||||
ASSETS |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,053,469 |
|
|
$ |
378,203 |
|
Short-term marketable securities |
|
— |
|
|
|
823,395 |
|
Accounts receivable, net |
|
144,249 |
|
|
|
137,849 |
|
Inventory, net |
|
105,463 |
|
|
|
85,876 |
|
Prepaid expenses and other current assets, net |
|
61,458 |
|
|
|
40,723 |
|
Total current assets |
|
1,364,639 |
|
|
|
1,466,046 |
|
Restricted cash |
|
114,270 |
|
|
|
111,214 |
|
Property and equipment, net |
|
155,299 |
|
|
|
145,915 |
|
Right-of-use assets, net |
|
147,566 |
|
|
|
158,849 |
|
Intangible assets, net |
|
25,267 |
|
|
|
25,921 |
|
Goodwill |
|
77,257 |
|
|
|
77,257 |
|
Other assets, net |
|
27,996 |
|
|
|
28,457 |
|
Total Assets |
$ |
1,912,294 |
|
|
$ |
2,013,659 |
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
93,514 |
|
|
$ |
54,442 |
|
Accrued compensation |
|
121,366 |
|
|
|
119,646 |
|
Accrued expenses |
|
79,291 |
|
|
|
77,889 |
|
Deferred revenue |
|
44,791 |
|
|
|
50,753 |
|
Total current liabilities |
|
338,962 |
|
|
|
302,730 |
|
Convertible senior notes, net |
|
1,502,943 |
|
|
|
1,504,000 |
|
Long-term operating lease liabilities |
|
166,312 |
|
|
|
178,463 |
|
Other long-term liabilities |
|
126,944 |
|
|
|
127,773 |
|
Total Liabilities |
|
2,135,161 |
|
|
|
2,112,966 |
|
Stockholders’ deficit: |
|
|
|
||||
Common stock, par value of |
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
3,009,424 |
|
|
|
2,900,056 |
|
Accumulated other comprehensive loss |
|
(5,563 |
) |
|
|
(4,852 |
) |
Accumulated deficit |
|
(3,226,729 |
) |
|
|
(2,994,512 |
) |
Total Stockholders’ Deficit |
|
(222,867 |
) |
|
|
(99,307 |
) |
Total Liabilities and Stockholders’ Deficit |
$ |
1,912,294 |
|
|
$ |
2,013,659 |
|
Guardant Health, Inc. Supplemental Revenue Information (unaudited) (in thousands) |
||||||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
|
|
|
||||||||||
Oncology |
|
$ |
219,105 |
|
$ |
158,685 |
|
$ |
424,059 |
|
$ |
309,244 |
Biopharma and data |
|
|
60,947 |
|
|
56,020 |
|
|
113,924 |
|
|
101,396 |
Screening |
|
|
52,866 |
|
|
14,814 |
|
|
94,456 |
|
|
20,491 |
Licensing and other |
|
|
2,060 |
|
|
2,569 |
|
|
4,204 |
|
|
4,428 |
Total revenue |
|
$ |
334,978 |
|
$ |
232,088 |
|
$ |
636,643 |
|
$ |
435,559 |
Reconciliation of Selected GAAP Measures to Non-GAAP Measures (unaudited) (in thousands, except per share data) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
|
|
|
|
|
|
|
|
||||||||
GAAP cost of revenue |
$ |
115,949 |
|
|
$ |
81,205 |
|
|
$ |
220,868 |
|
|
$ |
155,928 |
|
Amortization of intangible assets |
|
(150 |
) |
|
|
(150 |
) |
|
|
(298 |
) |
|
|
(298 |
) |
Stock-based compensation expense and related employer payroll tax payments |
|
(3,945 |
) |
|
|
(2,759 |
) |
|
|
(7,156 |
) |
|
|
(5,149 |
) |
Non-GAAP cost of revenue |
$ |
111,854 |
|
|
$ |
78,296 |
|
|
$ |
213,414 |
|
|
$ |
150,481 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP gross profit |
$ |
219,029 |
|
|
$ |
150,883 |
|
|
$ |
415,775 |
|
|
$ |
279,631 |
|
Amortization of intangible assets |
|
150 |
|
|
|
150 |
|
|
|
298 |
|
|
|
298 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
3,945 |
|
|
|
2,759 |
|
|
|
7,156 |
|
|
|
5,149 |
|
Non-GAAP gross profit |
$ |
223,124 |
|
|
$ |
153,792 |
|
|
$ |
423,229 |
|
|
$ |
285,078 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP research and development expense |
$ |
96,533 |
|
|
$ |
87,449 |
|
|
$ |
187,571 |
|
|
$ |
175,970 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
(16,025 |
) |
|
|
(14,255 |
) |
|
|
(30,474 |
) |
|
|
(27,345 |
) |
Contingent consideration |
|
— |
|
|
|
(647 |
) |
|
|
— |
|
|
|
(1,181 |
) |
Non-GAAP research and development expense |
$ |
80,508 |
|
|
$ |
72,547 |
|
|
$ |
157,097 |
|
|
$ |
147,444 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP sales and marketing expense |
$ |
189,954 |
|
|
$ |
119,588 |
|
|
$ |
359,086 |
|
|
$ |
223,904 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
(17,594 |
) |
|
|
(11,756 |
) |
|
|
(32,296 |
) |
|
|
(21,945 |
) |
Non-GAAP sales and marketing expense |
$ |
172,360 |
|
|
$ |
107,832 |
|
|
$ |
326,790 |
|
|
$ |
201,959 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP general and administrative expense |
$ |
61,660 |
|
|
$ |
50,259 |
|
|
$ |
119,586 |
|
|
$ |
97,211 |
|
Amortization of intangible assets |
|
(126 |
) |
|
|
(266 |
) |
|
|
(356 |
) |
|
|
(598 |
) |
Stock-based compensation expense and related employer payroll tax payments |
|
(24,842 |
) |
|
|
(14,832 |
) |
|
|
(44,351 |
) |
|
|
(28,403 |
) |
Contingent consideration |
|
(1,000 |
) |
|
|
(230 |
) |
|
|
(1,000 |
) |
|
|
(720 |
) |
Other |
|
(250 |
) |
|
|
— |
|
|
|
(1,400 |
) |
|
|
(2,000 |
) |
Non-GAAP general and administrative expense |
$ |
35,442 |
|
|
$ |
34,931 |
|
|
$ |
72,479 |
|
|
$ |
65,490 |
|
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
|
|
|
|
|
|
|
|
||||||||
GAAP loss from operations |
$ |
(129,118 |
) |
|
$ |
(106,413 |
) |
|
$ |
(250,468 |
) |
|
$ |
(217,454 |
) |
Amortization of intangible assets |
|
276 |
|
|
|
416 |
|
|
|
654 |
|
|
|
896 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
62,406 |
|
|
|
43,602 |
|
|
|
114,277 |
|
|
|
82,842 |
|
Contingent consideration |
|
1,000 |
|
|
|
877 |
|
|
|
1,000 |
|
|
|
1,901 |
|
Other |
|
250 |
|
|
|
— |
|
|
|
1,400 |
|
|
|
2,000 |
|
Non-GAAP loss from operations |
$ |
(65,186 |
) |
|
$ |
(61,518 |
) |
|
$ |
(133,137 |
) |
|
$ |
(129,815 |
) |
|
|
|
|
|
|
|
|
||||||||
GAAP net loss |
$ |
(120,142 |
) |
|
$ |
(99,899 |
) |
|
$ |
(232,217 |
) |
|
$ |
(195,058 |
) |
Amortization of intangible assets |
|
276 |
|
|
|
416 |
|
|
|
654 |
|
|
|
896 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
62,406 |
|
|
|
43,602 |
|
|
|
114,277 |
|
|
|
82,842 |
|
Contingent consideration |
|
1,000 |
|
|
|
877 |
|
|
|
1,000 |
|
|
|
1,901 |
|
Impairment of non-marketable equity securities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,000 |
|
Gain on extinguishment of convertible notes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,672 |
) |
Other |
|
250 |
|
|
|
— |
|
|
|
1,400 |
|
|
|
2,000 |
|
Non-GAAP net loss |
$ |
(56,210 |
) |
|
$ |
(55,004 |
) |
|
$ |
(114,886 |
) |
|
$ |
(116,091 |
) |
|
|
|
|
|
|
|
|
||||||||
GAAP net loss per share, basic and diluted |
$ |
(0.90 |
) |
|
$ |
(0.80 |
) |
|
$ |
(1.76 |
) |
|
$ |
(1.57 |
) |
Non-GAAP net loss per share, basic and diluted |
$ |
(0.42 |
) |
|
$ |
(0.44 |
) |
|
$ |
(0.87 |
) |
|
$ |
(0.94 |
) |
Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted |
|
132,867 |
|
|
|
124,114 |
|
|
|
132,074 |
|
|
|
123,993 |
|
Reconciliation of GAAP Net Loss to Adjusted EBITDA (unaudited) (in thousands) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
|
|
|
|
|
|
|
|
||||||||
GAAP net loss |
$ |
(120,142 |
) |
|
$ |
(99,899 |
) |
|
$ |
(232,217 |
) |
|
$ |
(195,058 |
) |
Interest income |
|
(10,199 |
) |
|
|
(7,560 |
) |
|
|
(21,350 |
) |
|
|
(16,672 |
) |
Interest expense |
|
1,346 |
|
|
|
983 |
|
|
|
2,693 |
|
|
|
1,774 |
|
Other expense (income), net |
|
(308 |
) |
|
|
25 |
|
|
|
(151 |
) |
|
|
(7,826 |
) |
Provision for income taxes |
|
185 |
|
|
|
38 |
|
|
|
557 |
|
|
|
328 |
|
Depreciation and amortization |
|
9,561 |
|
|
|
10,042 |
|
|
|
19,003 |
|
|
|
20,278 |
|
Stock-based compensation expense and related employer payroll tax payments |
|
62,406 |
|
|
|
43,602 |
|
|
|
114,277 |
|
|
|
82,842 |
|
Contingent consideration |
|
1,000 |
|
|
|
877 |
|
|
|
1,000 |
|
|
|
1,901 |
|
Other |
|
250 |
|
|
|
— |
|
|
|
1,400 |
|
|
|
2,000 |
|
Adjusted EBITDA |
$ |
(55,901 |
) |
|
$ |
(51,892 |
) |
|
$ |
(114,788 |
) |
|
$ |
(110,433 |
) |
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities (unaudited) (in thousands) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
|
|
|
|
|
|
|
|
||||||||
Net cash used in operating activities |
$ |
(57,778 |
) |
|
$ |
(60,285 |
) |
|
$ |
(123,401 |
) |
|
$ |
(122,974 |
) |
Purchases of property and equipment |
|
(11,759 |
) |
|
|
(5,649 |
) |
|
|
(17,339 |
) |
|
|
(10,108 |
) |
Free cash flow |
$ |
(69,537 |
) |
|
$ |
(65,934 |
) |
|
$ |
(140,740 |
) |
|
$ |
(133,082 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260730185180/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Meaghan Smith
press@guardanthealth.com
Source: Guardant Health, Inc.